You are not authorized to access this page.
Search Within

Kylee Maclachlan

Formats
  1. Meeting Abstract (114)
  2. Journal Article (31)
  3. Review (5)
  4. Research Letter (4)
  5. Editorial (2)
  6. Correspondence (1)
Groups
  1. GME, Medicine (157)
  2. Graduate Medical Education (157)
  3. Department of Medicine (137)
  4. Hematologic Malignancies, Division of (133)
  5. Center for Hematologic Malignancies (130)
  6. Myeloma (130)

More Groups

People
  1. Saad Usmani (123)
  2. Alexander Lesokhin (111)
  3. Malin Hultcrantz (103)
  4. Neha Korde (95)
  5. Urvi Shah (94)
  6. Heather Landau (93)

More People

Years
  1. 2025 (6)
  2. 2024 (49)
  3. 2023 (45)
  4. 2022 (31)
  5. 2021 (15)
  6. 2020 (11)
Publications
  1. Blood (70)
  2. Clinical Lymphoma, Myeloma and Leukemia (39)
  3. Blood Cancer Journal (7)
  4. Journal of Clinical Oncology (7)
  5. Blood Advances (6)
  6. Clinical Cancer Research (4)

More Publications

Publishers
  1. American Society of Hematology (76)
  2. Elsevier Inc. (44)
  3. Nature Publishing Group (13)
  4. American Association for Cancer Research (7)
  5. American Society of Clinical Oncology (7)
  6. Royal College of Pathologists of Australasia (1)

More Publishers

Results (157)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic determinants of resistance in newly diagnosed multiple myeloma treated with targeted-immunotherapy
    Meeting Abstract

    Maura, F.; Boyle, E.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Blaney, P.; Gagler, D.; Ziccheddu, B.; Ghamlouch, H.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Variability in pattern of mutational signatures in multiple myeloma as a function of racial origin
    Meeting Abstract

    Blaney, P.; Boyle, E. M.; Maclachlan, K. H.; Williams, L. S.; Gagler, D.; Sudha, P.; Poos, A. M.; Wang, Y.; Ghamlouch, H.; Tenenbaum, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Fc-mediated antibody effector function, inflammation resolution and oligoclonality on TCR rearrangements predict sustained MRD negativity in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Meeting Abstract

    Boyle, E. M.; Maura, F.; Coffey, D.; Maclachlan, K. H.; Diamond, B.; Ghamlouch, H.; Gagler, D.; Blaney, P.; Ziccheddu, B.; Wang, Y.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Clinical efficacy of daratumumab (DARA)-based second line therapy after DARAcontaining and DARA-free induction therapies in multiple myeloma: A single center experience
    Meeting Abstract

    Ciardiello, A.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Lu, S. X.; Patel, D.; Maclachlan, K.; Lahoud, O. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Evaluating serum-free light chain ratio as a biomarker for multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?
    Editorial

    Maclachlan, K. H.; Lesokhin, A. M.
    Cancer Cell (2022)

    Fulltext@MSK | Save
  • Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma
    Editorial

    Holstein, S. A.; Asimakopoulos, F.; Azab, A. K.; Bianchi, G.; Bhutani, M.; Crews, L. A.; Cupedo, T.; Giles, H.; Gooding, S.; Hillengass, J.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Chromothripsis as a pathogenic driver of multiple myeloma
    Review

    Maura, F.; Boyle, E. M.; Rustad, E. H.; Ashby, C.; Kaminetzky, D.; Bruno, B.; Braunstein, M.; Bauer, M.; Blaney, P.; Wang, Y.; more...
    Seminars in Cell and Developmental Biology (2022)

    Fulltext@MSK | Save